SCHEMBL3208367

SCHEMBL3208367

Cn1cc(-c2cccc(N3CCc4cc(C(C)(C)C)ccc4C3=O)c2CO)cc(Nc2ccc(C(=O)N3CC4(COC4)C3)cn2)c1=O

nearest known ligand 0.73

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BTK Q06187 19/20 0.73
CLK2 P49760 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1724202 0.93 BTK (0.84) BTKCLK2
SCHEMBL12850580 0.92 BTK (0.69) BTKCLK2
SCHEMBL3197442 0.90 BTK (0.73) BTKCLK2
SCHEMBL3207931 0.90 BTK (0.67) BTKCLK2
SCHEMBL3211627 0.89 BTK (0.81) BTKCLK2
SCHEMBL3212147 0.88 BTK (0.80) BTKCLK2
SCHEMBL3205633 0.86 BTK (0.81) BTKCLK2
SCHEMBL1726525 0.86 BTK (0.73) BTKCLK2
SCHEMBL3208530 0.84 BTK (0.81) BTK
SCHEMBL16013528 0.84 BTK (1.00) BTKCLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683064-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2010-03-23 US claimed
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-12-10 US claimed
EP-2242749-B1 NOVEL PYRIDINONES AND PYRIDAZINONES HOFFMANN LA ROCHE (CH) 2013-04-10 EP disclosed
US-7906509-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2011-03-15 US disclosed
US-7906509-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2011-03-15 US disclosed
US-20100099659-A1 Inhibitors of Bruton's Tyrosine Kinase KENNEDY-SMITH JOSHUA 2010-04-22 US disclosed
US-20100099659-A1 Inhibitors of Bruton's Tyrosine Kinase KENNEDY-SMITH JOSHUA 2010-04-22 US disclosed
US-7683064-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2010-03-23 US disclosed
US-7683064-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2010-03-23 US disclosed
US-7683064-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2010-03-23 US disclosed
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-12-10 US disclosed
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-12-10 US disclosed
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099659-A1 Inhibitors of Bruton's Tyrosine Kinase BTK, SYK, LYN BTK 1/4885CLK2 575/4885
US-20090306041-A1 Inhibitors of Bruton's tyrosine kinase BTK, SYK, LYN BTK 1/4885CLK2 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.